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Abstract
Over the past decade, there have been great innovations in the diagnosis of 
venous disorder since the introduction of dual-source computed tomography 
(DSCT) in 2006. It provides fast and reliable diagnosis of deep vein thrombosis 
(DVT) with the capability of full leveling of thrombus burden and allows early 
endovascular interventions with pharmacomechanical aspiration thrombectomy 
(PMAT) being performed aiming to reduce the post-thrombotic syndrome (PTS) 
and improve quality of life. The newly introduced ultrafast clot removal system, 
in patients who failed with PMAT, AngioJet, and EKOS, aids in rapid restoration 
of venous flow and decline of venous hypertension to mitigate the valve damage. 
Percutaneous transluminal angioplasty (PTA) and stenting yield high technical 
success rate of 93–96% and a promising short-term 1-year and 2-year patency of 
around 93% and 75–79%, respectively, for symptomatic May-Thurner syndrome 
(MTS). Based on the cumulative endovascular treatment experience in over 2000 
cases in Xizou, China, some relevant precipitating factors are addressed, and a 
new classification of subtypes have been proposed to guide the proper selection of 
endovascular management of Budd-Chiari syndrome (BCS).
Keywords: deep vein thrombosis, computed tomographic venography, magnetic 
resonance venography, digital subtraction angiography, May-Thurner syndrome, 
Budd-Chiari syndrome, catheter-directed thrombolysis, pharmacomechanical 
aspiration thrombectomy, percutaneous transluminal angioplasty, stenting
1. Lower-limb deep vein thrombosis (DVT)
1.1 Introduction and background
It has been estimated that approximately 200,000 to 250,000 cases of lower-
limb DVT occurred annually in the USA [1, 2]. Dated back as early as in 1860, 
German pathologist Rudolf Virchow initially depicted the gold rules of pathophysi-
ology involved in DVT: the triad of (1) venous stasis, (2) endothelial damage, and 
(3) hypercoagulability. Venous stasis can be resulted from external compression, 
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traumatized venous wall injury as a consequence of indwelling catheters and 
devices, and infusion of chemotherapeutic agent and lipid substance as prescribed 
in hyperalimentation, as well as in lower cardiac output state and prolonged immo-
bilization. Hypercoagulability is generally linked to hematological and genetic 
disorders, i.e., polycythemia rubra vera, antithrombin III deficiency, protein S/C 
deficiency, hyperhomocysteinemia, and cancerous disease, oral contraceptive and 
tobacco use, as well as pregnancy and postpartum state [3, 4].
2. Clinical presentations
The most common symptoms and signs in acute DVT (<2w) are a tender and 
swollen lower limb along with local heat on palpation. In subacute (2w–6 m) and 
chronic (>6 m) DVT, patients usually presented with chronic lower-limb swelling, 
pigmentation, and ulceration in lower calf and ankle. Among the complications 
resulted from lower-limb DVT, the most serious one is acute pulmonary embolism, 
which can precipitate acute pleuritic chest pain, tachycardia, hypotension, hypoxia, 
and death from acute decompensated right heart failure in those patients presented 
with massive pulmonary embolism. Despite adequate medication used, post-
thrombotic syndrome occurs in approximately 20–40% of patients with subacute 
and chronic lower-limb DVT [2–4].
3. Diagnostic imaging modalities
A diversity of imaging tools, i.e., ultrasonography with color-flow mapping, CT 
venography, MR venography, radionuclide venography, and contrast venography, 
have been implicated in the diagnosis of lower-limb DVT.
3.1 Ultrasonography (US)
Grayscale ultrasonography is the first-line tool, which can delineate low echo-
genicity or nearly anechoic thrombi and a non-compressible vein in acute DVT, 
with a sensitivity and specificity of 90–100%, respectively. In chronic DVT, diagno-
sis can be made on the basis of detecting (1) a thickened vein wall with hyperechoic 
intraluminal projections, (2) a non-compressible vein, (3) little or no change of vein 
caliber with flow augmentation, and (4) the presence of collateral vessels. Color-
flow Doppler ultrasound can assist in the detection of a patent versus non-patent 
venous lumen [5, 6]. The limitations of US are the inconsistency in the depiction 
of below-knee venous thrombi in terms of anatomical variants and small caliber as 
well as potential difficulty in assessing iliac veins [7].
3.1.1 Contrast venography
Prior to the invention of US, contrast venography, done with cannulation of a 
sizable pedal vein and a tourniquet compressing at the ankle, on a remote control 
unit with tilting facility, had been the diagnostic gold standard of lower-limb 
DVT. However, the foot back tends to be congestive and swollen, and a sizable 
vein for cannulation may not be available. A couple of methods have been raised to 
enhance the detectability including limb elevation and Ace wrap, digital compres-
sion, nitroglycerin paste, Doppler US localization with a pencil probe, and surgical 
cutdown. Technical difficulty does exist. In addition, there are certain diagnostic 
pitfalls and tricks that may result in false-positive and false-negative consequences, 
3Venous Interventions: From Lower-Limb Deep Vein Thrombosis to May-Thurner Syndrome and…
DOI: http://dx.doi.org/10.5772/intechopen.85363
mainly incomplete contrast opacification of the deep venous system and a variety of 
artifacts that may mimic intraluminal clots [8–10].
In acute DVT, the hallmark features are the detection of filling defects 
(thrombi) with simulated “tram-tracking sign” appreciated between the venous 
lumen and the venous wall and the acute venous cutoff identified not at the valve 
region. The affected veins tend to get distended along with the increased thrombi 
burdens [3, 9, 10]. In chronic DVT, the hallmark features are (1) clot retraction, (2) 
clot recanalization, (3) valve destructions, and (4) loss of normal venous pathway. 
In selective minor case, the affected veins may recanalize completely and appear 
essentially normal [10].
3.2 Magnetic resonance venography (MRV)
Over the past decade, there have been remarkable advances in the magnetic 
resonance (MR) imaging technology of deep venous system that prompt both non-
contrast-enhanced and contrast-enhanced MRVs nearly as comparable as contrast 
venography in the diagnostic accuracy of DVT [11–13]. As shown in 2007, one meta-
analysis evaluated the diagnostic sensitivity and specificity of MRV in lower-limb 
DVT to be 92 and 95%, respectively [14]. Aside from claustrophobia, the limitations 
of MRV include a lengthy procedure time, pregnancy, and patient with renal failure 
and with implanted metallic devices.
3.3 Computed tomographic venography (CTV)
CTV had been used for diagnosis of DVT at the single-slice CT era [14, 15]. Over 
the past decade with the emergence of dual-source computed tomography (DSCT) 
in 2006 by Siemens, tremendous advances in fundamental technology and clinical 
utility of CTV have been brought about. In our institution, since the availability of 
the second-generation DSCT (Somatom Definition Flash, Siemens) in September 
2009, we were able to develop our own scanning protocol in CTV with superb imag-
ing quality in the majority of the patients around 2013 (Table 1 and Figure 1). Proper 
opacification of deep venous system of lower limb, starting from the lower inferior 
vena cava (IVC) down to the mid-level of tibioperoneal veins, can be acquired as 
a routine (Figure 2). Except in some selective patients with idiopathic increase in 
below-knee peripheral vascular resistance (PVR) and in patients with advanced 
1. Anatomic collimation: Aortic bifurcation at L3–L4 level to toes
2. Contrast bolus injection:
 120–140 ml of Ultravist 370 mg I/ml
 BMI: <23.9 120 ml, 24–27.9 130 ml, > 28 140 ml
 Flow rate: 4 ml/s, followed by a 40 ml saline chasing
3. Scan initiation: 3 min after contrast bolus
4. Scan mode: Flash
5. Scan parameters
 Acquisition: 128 × 0.6 mm
 Slice thickness: 5 mm
 Pitch: 2.5
6. Dose modulation: Care dose 4D
7. Effective radiation dose: 4–5 msv
Table 1. 
Dual-source CT venography protocol.
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peripheral arterial obstructive disease (PAOD), both of which result in sluggish input 
arterial flow and thus suboptimal venous opacification at CTV. In patients suspected 
of coexisting PAOD, a CT arteriography can be performed in one set prior to proceed-
ing of CTV (Figure 3). Approximately 80 ml of 370 mgI contrast medium is injected 
at rate of 4 ml/s, and the collimation is made at 64 × 0.6 mm to cover shortly above 
the aortic bifurcation down to the toes. The CTA is displayed in maximum intensity 
projection (MIP) and bone removal to facilitate visual reading. The tibioperoneal 
artery greater than 1.5 mm can be well delineated; however, in the lower calf where 
close alignment of the artery is adjacent to the bone cortex, loss of artery outline may 
be encountered due to equalization of post-processing threshold.
In a recent meta-analysis focused on the diagnosis of lower-limb DVT, the 
cumulative sensitivity and specificity are 96 and 95%, respectively [16]. The limita-
tions of CTV are patients with significant renal failure, with idiopathic increase in 
below-knee PVR, and with severe PAOD.
Figure 1. 
(a-d) CTV depicted optimal opacification of venous structure from bifurcation of IVC to the lower level of 
popliteal veins.
Figure 2. 
(a–e) CTV depicted extensive DVT from the LCIV to tibioperoneal veins (arrows).
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4. Indication for endovascular interventions in DVT
4.1 Introduction and background
Anticoagulation therapy has long been the first-line management in patients 
presented with acute DVT. In the 1980s, systemic thrombolysis using streptokinase 
demonstrated better resolution of thrombus than heparinization alone but carried 
an unacceptable risk of bleeding complication [17]. It was until the late 1990s when 
intraluminal catheter-directed thrombolysis (CDT) was initiated as an adjuvant to 
treat those patients in whom heparin worked slowly and patient could not tolerate 
intractable swelling of the affected lower limb. The treatment safety and the clini-
cal efficacy of CDT were validated in iliofemoral DVT by Bjarnason et al. in 1997 
[18]. Within the following years, after conducting a nationwide multicenter study, 
Mewissen et al. proposed that CDT was safe and effective and to be preferentially 
carried out in proximal iliofemoral and femoropopliteal DVT in patients presented 
Figure 3. 
CT arteriography at the same set as CTV showed high-grade imaging quality as well as identification of two 
discrete obstructions in the right iliac and superficial femoral arteries. Collateral arteries were also clearly 
depicted.
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with symptomatic venous obstruction [19]. In 2006, the Society of Interventional 
Radiology published the guidelines for the treatment of lower extremity deep vein 
thrombosis [20]. (1) In a clinical subset of patients objectively documented with 
iliofemoral DVT, early debulking of thrombus burden can help mitigate post-throm-
botic syndrome (PTS). (2) In patients presented with severe symptoms of massive 
swelling and intractable pain, early intervention helps reduce mobility and prevent 
progression to venous gangrene (Table 2). As the thrombus ages, approximately 10 
to 14 days after acute onset, CDT becomes less effective in terms of thrombus deb-
ulking. As indicated in the CaVenT study, the incidence of PTS reduced to 14.4%, 
and the 6-m venous patency rate was 65.9% in CDT vs. 47.4% in control, respectively 
(p = 0.012) [21]. The long-term outcome of the ATTRACT study, a multicenter 
randomized controlled trial, was published in The New England Journal of Medicine 
in December 2017. The result showed no reduction of overall PTS at 2 years (48.0% 
vs. 47.4%), but a noteworthy difference of 6% declines in moderate-severe degree of 
PTS (24% vs. 18%, p = 0.04) [22]. Given that primary endpoint was not achieved, 
however, in selective patients presented with profound DVT symptoms and lower 
risk of bleeding, the benefit of CDT in reducing moderate-severe PTS and earlier 
symptomatic relief [23, 24] may gain reappraisal by clinicians and interventional 
radiologists. In addition, patients presented with significant venous steno-occlusive 
disease after CDT can be managed concomitantly with percutaneous transluminal 
angioplasty (PTA) or stent deployment to prevent recurrence of DVT [25].
4.2 Current technology in endovascular managements of DVT
4.2.1 Patient selection
In our institution, patients suspected of having DVT routinely received color-
flow mapping and Doppler US and CTV. In advanced symptomatic patients 
presented with CT documentation of high-level (femoroiliac veins) or extensive 
involvement beyond popliteal and tibioperoneal veins but with lower risk of bleed-
ing, CDT is conducted with pharmacomechanical thrombolysis with continued 
infusion of urokinase for 48–96 hours with an aim for early thrombus debulking 
and rapid symptomatic relief. While those presented with mild to moderate symp-
tom and CTV documented popliteal and/or tibioperoneal DVTs, conventional 
anticoagulation is justified.
4.2.2 Access site of CDT
Typically, with the patient in prone position, the popliteal vein of the affected 
limb is accessed with US guidance. A 3-F micropuncture set (Cook Corporation, 
Indiana, USA) is used for a safe puncture and access into the popliteal vein as well as 
to prevent subsequent focal bleeding. The cannula is replaced with a 9-F introduc-
ing sheath for easy venous access.
1. Percutaneous aspiration thrombectomy
2. Percutaneous pharmacomechanical thrombectomy
3. AngioJet (rheolysis)
4. Device-assisted thrombolysis
 Balloon-assisted system
 Ultrasound-assisted system (EKOS)
Table 2. 
Methods of endovascular interventions for deep vein thrombosis.
7Venous Interventions: From Lower-Limb Deep Vein Thrombosis to May-Thurner Syndrome and…
DOI: http://dx.doi.org/10.5772/intechopen.85363
4.2.3 CDT with pharmacomechanical aspiration thrombectomy (PMAT)
A 5-F pigtail catheter was inserted through the sheath, which is moved up and 
down a couple of times through the thrombosed segment in popliteofemoroiliac 
veins, accompanied with simultaneous infusion of 100,000–250,000 IU of uro-
kinase, to assist macerating the thrombus burden for 15 min. An 8-F 60-cm-long 
multipurpose guiding catheter, attached with a 50-ml syringe, is used to aspirate 
the macerated thrombi (Figure 4). In the case presented with significant residual 
thrombi, a multi-slit infusion catheter of suitable length (Fountain infusion catheter, 
Merit, USA) was embedded into the distal-most segment and spared the proximal-
most segment for sustained continual infusion of 500,000–1,000,000 IU of uroki-
nase per 24 hours for up to 48–96 hours. The patient is kept in a ACU/ICU for close 
monitoring of general condition and bleeding. Concomitant intravenous infusion 
of heparin 20,000 IU per 24 hours to prevent new thrombus formation around the 
infusion catheter was also deemed necessary. Daily check of aPTT (<1.5 time of 
control level) and fibrinogen and platelet count was mandatory. The patient is sent 
back to DSA suite every 8–12 hours to check for the resolution of thrombi and reposi-
tioning of infusion catheter to facilitate further thrombus resolution toward the 
proximal end until satisfactory results are achieved. The infusion dose of urokinase 
can be adjusted depending on the bulk of residual thrombi. After successful CDT, 
the patient is put on anticoagulation with warfarin for at least 6–12 months.
4.2.4  CDT with new devices by using pharmacomechanical catheter-directed 
thrombolysis
The consensus that the earlier the thrombi lysed, the less severe the PTS will be 
paves the way for a better quality of life and less daily limitation of physical activity. 
Speedy thrombus resolution to salvage valve damage and venous insufficiency sounds 
reasonable and practical. In recent years, an ultrasound-emitting thrombolytic infu-
sion catheter (EKOS Corporation, Bothell, WA) and the AngioJet Rheolytic Catheter 
System (MEDRAD Interventional, Minneapolis, MN) have become available in our 
institution (Table 2). In terms of being high-cost treatment modalities, they both are 
reserved for those patients who failed to respond well with PMAT (Figures 5 and 6).
Figure 4. 
Relatively fresh and subacute thrombi were aspirated by PMAT from the left iliofemoral veins in a 32-year-old 
female taking oral contraceptive pills for dysmenorrhea.
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Figure 5. 
An 81-year-old female with lower third esophagus adenocarcinoma, cT3N0Mb, Stage III under palliative 
chemotherapy, suffered from left leg swelling, and CTV documented massive DVT in iliofemoropopliteal veins. 
(a and c) Nearly complete obstruction of left iliofemoropopliteal veins by DVT. (b and d) s/p EKOS catheter 
for enhanced CDT treatment and s/p PTA and Wallstent deployment in left common and external iliac vein 
restored good blood flow.
4.2.5 Percutaneous transluminal angioplasty and stenting
After successful PMAT is achieved, the whole affected proximal venous path-
way should be documented with DSA for any residual steno-occlusive disorder. 
A 0.035″ hydrophilic guide wire (Terumo, Tokyo Japan) is negotiated, and a 4-F 
Teflon-coated catheter (Terumo, Tokyo Japan) is advanced through the lesion. A 
0.035″ stiff hydrophilic guide wire (Terumo, Tokyo Japan) is exchanged. Sequential 
ballooning was conducted, with 3-mm, 5-mm, and 8-mm balloons until the balloon 
waist was completely gone, to accommodate a self-expandable stent of sufficient 
size and length, mainly the Wallstent (Boston Scientific, Massachusetts, USA). 
Postdeployment dilation is carried out with a balloon catheter of appropriate size 
to scaffold the venous fibrosis that frequently comes across with significant venous 
stenosis. Follow-up DSA is performed to document the technical success, which 
is graded as a residual stenosis of <30% [26, 27] (Figure 7). Aspirin 100 mg and 
clopidogrel 75 mg are recommended for at least 3 months after stenting.
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Figure 6. 
A 31-year-old obese male with hypertension suffered from gunshot wound over the abdomen and complicated 
with diffuse right leg iliofemoral DVT. (a and c) Diffuse DVT in the right iliofemoropopliteal veins due to 
immobilization. (b and d) After AngioJet, good blood flow regained.
Figure 7. 
A 48-year-old male developed chronic DVT in the left iliofemoral veins as a complication of dwelling perm 
catheter and successfully managed with PTA and two overlapping 8 m and 10 cm Wallstents. At 8-year 
follow-up, the stents remained patent. (a) Contrast venography revealed long-segment stenosis of the left 
iliofemoral veins and venous collaterals. (b) Balloon waist at predilation with an 8-mm balloon catheter. (c) 
Immediately after stenting, good flow is restored and minimal venous collaterals visualized.
Embolic Diseases - Evolving Diagnostic and Management Approaches
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5. Endovascular management of May-Thurner syndrome (MTS)
5.1 Introduction and anatomical background
MTS has two synonyms: Cockett syndrome and iliac vein compression syn-
drome. In 1983, Dr. Ernest Ferris for the first time proposed May-Thurner syndrome 
in memory of Dr. May and Dr. Thurner for their relevant contributions [28]. The 
first description of a septum-like structure in the left common iliac vein (LCIV) 
was made in 32% (10 out of 32) of cadavers, in 1906 by an anatomist McMurrich, 
with which a congenital remnant was implicated as such [29]. In 1943, Ehrich and 
Krumbhaar through anatomic dissection in 412 cadavers found that obstructive 
lesion in the left common iliac vein (LCIV) in 23.8 and 33.8% of the lesion occurred 
after the first decade. The lesions were regarded as acquired and not congenital. In 
1957, May and Thurner, through autopsy in 430 cadavers, demonstrated that among 
19% of cadavers, the overriding right common iliac artery (RCIA) compressed the 
LCIV against the spine [30]. Other investigators also presented different incidence 
of spurs in the LCIV by different imaging tools: 14% by Negus et al. [31], 50% by 
Vollman et al. with vascular endoscopy [32], and 62% by Juhan et al. with contrast 
venography [33], respectively.
5.2 Pathophysiology of MTS
Long-lasting pulsatile injury elaborated by the overlying RCIA prompted 
projectile fibrotic spurs into the lumen of the LCIV, which in turn resulted 
in accumulation of elastin and collagen over the spurs and extensive intimal 
proliferation of venous wall. Three varieties of classic venous spurs had been 
addressed, especially associated with a lower bifurcation position of the abdomi-
nal aorta [29]. Other theories had been implicated as possible causative factors, 
namely, compression by pregnant uterus [34] and by sigmoid colon associated 
with constipation [35]. Currently, with availability of modernized cross-sectional 
imaging modalities, like intravascular ultrasound and optic coherence tomogra-
phy, the venous spurs can be well depicted and precisely documented the severity 
of venous obstruction than contrast venography [36–38]. Regardless of spur-
forming mechanism [36], congenital or acquired, in case predisposed to hyperco-
agulability, thrombosis of the LCIV then issues initially at the stenosed segment 
and propagates in antegrade and retrograde fashions. However, in chronic MTS, 
the patient may be asymptomatic for quite a certain period of time if sufficient 
venous collaterals have developed [39].
5.3 Clinical manifestation and staging
MTS has a strong tendency to affect young and middle-aged woman (mean 
age, 42 y/o), although it does affect man [40]. In acute stage, the majority of 
patients frequently presented with sudden onset of pain and swelling of the left 
lower extremity due to the accompanying DVT. In chronic stage, the symptoms 
may be more or less vague to define but generally comprised of persistent edema, 
heaviness, lower calf and ankle skin pigmentation, venous claudication, and ulcer 
as well as varicose veins [41, 42]. Rarely, in some selective patients affected with 
phlegmasia alba dolens and phlegmasia rubra dolens, limb salvage may provide 
an extremely difficult challenge for the multidisciplinary team physicians. Based 
on the clinical and imaging findings, MTS is classified into three stages: Stage I, 
asymptomatic LCIV compression; Stage II, presence of intraluminal venous spurs; 
and Stage III, occurrence of DVT in the LCIV (Figure 8) [43, 44]. Failure to correct 
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the underlying anatomic substrate of the LCIV, complication of MTS can include 
pulmonary embolism, chronic venous stasis, PTS, and iliac vein rupture [39].
5.4 Diagnostic imaging modalities of MTS
As mentioned in the imaging diagnosis of DVT, a variety of imaging tools can 
offer a figure of diagnostic sensitivity and specificity. Each has its own advantages, 
disadvantages, and limitations. Among them, US is the first-line followed by CTV, 
MRV, and contrast venography to objectively document the level of DVT and grade 
the severity of iliac vein obstruction. A stenosis of >50% in the LCIV is considered 
as hemodynamically significant. As the stenosis percentage of the LCIV may be 
periodically altered with the circulating blood volume and the body position [38, 39], 
in suspicious case, a pressure gradient across the RCIV and LCIV of >2 mmHg 
at rest and > 3 mmHg with exercise aids in making a definite diagnosis. Over the 
past decade with the availability of second generation of DSCT scanner (Somatom 
Definition Flash, Siemens) in our institution, CTV has nearly replaced others 
and become the first-line imaging modality for MTS in terms of rapid dataset 
acquisition and precise leveling of steno-occlusion of the LCIV and the associ-
ated DVT [45–47]. In conjunction with 3-D volume rendering technique at CTA, 
the compressed segment of the LCIV by the overlying RCIA can be appreciated 
more precisely than contrast venography. Of paramount importance is the precise 
depiction of floating thrombi in the lower segment of the IVC with CTV, which 
may prompt the strategy to implant a temporary IVC filter to prevent pulmonary 
embolism during endovascular procedure.
5.5 Endovascular treatment of MTS
The endovascular treatment of MTS by PTA and stenting has been reported in 
the literature to be minimally invasive, technically feasible, and safe and clinically 
effective. Isolated PTA is not effective, similar to the result in other large central 
veins. The access site is from the left popliteal or common femoral veins.
Figure 8. 
Classification of MTS into three clinical stages. (a) CTV showed Stage I MTS 9 (arrow) incidentally while 
imaging of DVT. (b) CTV showed Stage II MTS presented with venous spur. (c and d) CTV showed Stage III 
MTS presented with DVT (black arrow).
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5.5.1 Percutaneous CDT in the treatment of MTS with extensive DVT
Pharmacomechanical aspiration thrombectomy (PMAT), as described in the 
treatment of isolated DVT, is well suited for MTS in acute stage presented with 
extensive thrombi, which is thoroughly dictated in Subsection 4.2.3.
5.5.2 Percutaneous transluminal angioplasty (PTA) and stenting for MTS
In patients with isolated stenosis but free of DVT, PTA and stenting are a 
straightforward procedure. In 1995, Berger et al. reported the first successfully 
Figure 9. 
A 70-year-old male with Stage III MTS successfully treated with PTA and stenting. (a) CT topography 
showed remarkable swelling of the entire left lower extremity. (b) CTV incidentally showed Stage II MTS 
half year age at workup for colon cancer. (c) CTV showed Stage III MTS with diffuse DVT from the upper 
left tibioperoneal vein to the common iliac vein. (d) Contrast venography showed minimal floating thrombin 
into the IVC (arrow). (e) A Teflon-coated 4-F catheter successfully navigated through the tight stenosis in the 
common iliac vein (arrow). (f) After sequential PTAs, a minimal channel was reanalyzed in the LCIV. (g 
and h) After a 14 mm x 80 mm Wallstent deployment and thrombolysis with a multi-slit infusion catheter for 
48 hours, successful recanalization was achieved. (i) At discharge (8 days after admission), the left leg limb was 
even smaller than the right leg.
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deployed stent to decompress left iliac vein obstruction. After successful PMAT 
is achieved, as done exactly in the treatment of DVT section, a 0.035″ hydrophilic 
guide wire (Terumo, Tokyo Japan) is vigorously negotiated through the steno-
occlusion in the LCIV, and a 4-F Teflon-coated catheter (Terumo, Tokyo Japan) 
is advanced in to the lower IVC. A 0.035″ stiff hydrophilic guide wire (Terumo, 
Tokyo Japan) is exchanged. Sequential ballooning was conducted, with 3-mm, 
5-mm, and 8-mm balloons until the balloon waist is completely gone, to accom-
modate a self-expandable stent of sufficient size and length. Wallstents (Boston 
Figure 10. 
A 65-year-old schizophrenic female suffered from subacute Stage III MTS, successfully recanalized with PMAT 
and Wallstent deployment. (a–e) CTV showed excellent depiction of massive DVT spanning from the lower 
IVC down to the left tibioperoneal vein. (f and g) Venography demonstrated floating thrombi in the lower 
IVC (arrow), and an Optease caval filter was implanted to prevent pulmonary embolism. (h–j) Subacute 
thrombi were removed with aspiration thrombectomy. (k and l) After aspiration thrombectomy, venography 
revealed minimal residual thrombi and long-segment tight steno-occlusion of left iliofemoral veins and venous 
collateral. (m and n) After sequential PTAs and Wallstent deployment, the venous flow was restored, and at 
2.5-year follow-up, the stent remained patent.
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Scientific, Massachusetts, USA) of 12–14 mm in diameter and 80–120 mm in 
length are used to span the lesion. During the deployment, the Wallstent is initially 
deployed in the lower IVC, after which the whole unit is pulled down to retain a 
distal landing zone in IVC of approximately 1–1.5 cm and spans over the entire 
steno-occlusive segment with a proximal landing zone of >2 cm. Postdeployment 
dilation is carried out with a balloon catheter of appropriate size to scaffold the 
venous spurs and fibrosis that frequently accompany MTS. Follow-up DSA is 
performed to document the technical success, which is graded as a residual stenosis 
of <30% (Figures 9–11) [26, 27]. Aspirin 100 mg and clopidogrel 75 mg are recom-
mended for at least 3 months after stenting. Kaplan-Meier life table analysis is 
used to calculate the primary and secondary patency rate in the follow-up periods. 
Repeat PTA/stenting as indicated is relevant to maintain the long-term patency.
5.5.3 Technical success and treatment outcome of MTS
As reported in the literature, the technical success rates ranged between 93 
and 96% [42–44, 47]. With repeat PTA/stenting, the midterm patency rates were 
Figure 11. 
A 41-year-old with MTS Stage III presented in acute stage was successfully managed with PMAT, PTA, and 
stenting. (a–c) CTV depicted extensive DVT in the left femoroiliac veins. (b) Pre-treatment photo showed 
swelling of the left leg and cellulitis. (e) Posttreatment photo showed disappearance of swelling and healing of 
cellulitis at 1-month follow-up. (f and g) Venography showed extensive DVT above the left femoral vein and 
relatively fresh thrombi obtained by PMAT. (h and i) After PTA and stenting in the LCIV, good patency was 
depicted, and minimal residual thrombi were treated with warfarin.
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promising and ranged between 95 and 100% [47, 48]. Although the prevalence of 
overall PTS did not decline with the adjunct use of PMAT, however, the reduction 
of moderate to severe degree of PTS was noteworthy. As to the long-term patency, it 
reserves meticulous monitoring.
6. Budd-Chiari syndrome
Budd-Chiari syndrome (BCS) occurs when obstruction of the hepatic venules 
anywhere along the inferior vena cava (IVC) to the right atrium junction can 
lead to portal hypertension. BCS can be life-threatening. The prevalence of 
BCS has different geographic variances. In Western countries, the prevalence of 
BCS is rare, occurring in about 1 in every 2.5 million people, whereas in some 
Asian countries, such as China, India, and Nepal, BCS is a common disease. For 
instance, in China’s Yellow River and Huaihe River region, 6.8–12 people per 
100,000 people suffer from BCS; and more than 20,000 BCS have been docu-
mented in China [49]. Differences in obstruction sites can also be seen between 
Western and Asian populations. In the West, hepatic vein occlusion is more 
common, and venous congestion involving the IVC is less documented. However, 
in Asia, the diaphragm-type Budd-Chiari syndrome accounts for as high as 70% 
of all cases. Geographical variance, obstruction location, and pathological and 
anatomical differences have led to significant differences in clinical symptoms, 
treatments, and prognosis of BCS in the East and West. The development of 
modern imaging has enabled observing the hepatic vein, portal vein, inferior vena 
cava, and azygous vein in vivo, which revealed discordances in comparison to tra-
ditional liver biopsy and autopsy findings as described in the previous literature. 
Therefore, it is necessary to revisit BCS.
6.1 Etiology
BCS is considered primary or secondary based on the origin of the hepatic venous 
outflow obstruction. When the hepatic vein outflow tract is compressed or infiltrated, 
it is regarded as secondary BCS. Some examples include a primary or metastatic 
tumor of the liver, leiomyomas of the inferior vena cava, and tumor thrombus. So far, 
the most common etiology of primary BCS in Western countries is thrombosis, and 
25–46% of patients are in prethrombotic or hypercoagulable states. Therefore, pri-
mary BCS is predisposed by prethrombotic conditions [50]. However, in China, the 
etiology of BCS is different. The current research shows that in China, the primary 
thrombotic disease is not a common cause of BCS. Studies have demonstrated that (1) 
patients with inferior vena cava obstruction have elevated blood vascular endothelial 
growth factor (VEGF) [51], (2) there is higher groundwater iodine concentration 
in high-prevalence areas [52], (3) BCS patients have higher blood and urine iodine 
concentrations [53], (4) people living in rural areas have a higher prevalence, (5) 
restenosis can occur despite balloon venoplasty of the hepatic vein and inferior vena 
cava [54], and (6) membranous reformation can occur despite surgery.
Statistical analysis of 2406 patients found that the proportion of hepatic vein 
occlusion in adolescents under 30 years of age was significantly higher than in 
patients over 30 years of age [55, 56]. The proportion of inferior vena cava obstruc-
tion increases with increasing age in patients aged 30–79 years old. In 256 BCS 
patients in the 60–69 age group, 222 cases have inferior vena cava obstruction, and 
34 cases have hepatic vein obstruction (7.2%); only 1 case of 34 cases of BCS in 
70–79 years old was hepatic vein obstruction type (2.9%).
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6.1.1 Iodine and vascular endothelial proliferation
Guo et al. found that in the groundwater iodine concentration of drinking water in 
128 patients with inferior vena cava obstruction in Heze, Shandong Province, 98.44% 
of the 128 patients had iodine content of 150 μg/l or more, of which 150–300 μg/l 
accounted for 27.35% and 300 μg/l accounted for 71.09%. This result indicates that 
an area with high groundwater iodine concentration is at high risk of developing 
BCS [52]. Further studies by Zhuang et al. found that blood iodine levels in 233 BCS 
patients were also higher than that in the healthy population [53] (see Table 3).
The results showed that the serum iodine concentration of BCS patients was more 
than five times higher than that of the control group. On this basis, we tested the urine 
iodine of BCS patients and found that the urinary iodine of BCS patients was also 
higher than the average population. Li et al. carried out in vitro research on the culture 
of umbilical vein endothelial cells and fibroblasts using different concentrations of 
iodide culture medium. It was found that at iodine concentration of 300–500 μg/l, the 
proliferation of vascular endothelial cells and hyperplasia of fibroblasts can be induced. 
It is speculated that high iodine concentration can lead to vascular endothelial cell pro-
liferation [57, 58]. Our study of the inferior vena cava septum revealed that the vascular 
endothelium of the inferior vena cava gradually thickened and merged into a septum. 
The structure of the septum was fibrous connective tissue in the middle, and the upper 
and lower layers were vascular endothelium (Figure 12). However, the mechanism of 
how vascular endothelial cells migrate to form inferior vena cava septum is still unclear.
6.1.2 Vascular endothelial growth factor (VEGF)
In studies using enzyme-linked immunosorbent essay of 40 patients with 
inferior vena cava obstruction, Han et al. revealed that patients with inferior vena 
Group n Serum iodine (μg/l) Ranges (min-max)
IVC-type BCS 144 347 ± 272.3a 4.3–1095.1
HV-type BSS 71 237 ± 231.1a 12.3–937.2
MIX-type BCS 18 307 ± 134.4a 72.1–512.7
Control group 60 76.3 ± 25.7 30.2–97.4
Values are given as means±SD. 
aVersus control group (p < 0.05)
Table 3. 
Serum iodine levels in patients with BCS in different types and in the control group.
Figure 12. 
Thickening of the vascular endothelium above the inferior vena cava septum (a). Lateral migration of 
thickened vascular endothelium cells and fibrous connective tissue forming the septum (b).
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cava obstruction have serum VEGF concentration four times higher than that of 
the control group. These findings hint that the formation of the IVC septum may be 
related to inferior vena cava endothelial damage and repair [51] (see Table 4).
6.1.3 Abnormal bone marrow hyperplasia and gene mutation
A significant advance in myeloproliferative neoplasm research was the discovery 
of the Janus kinase 2 (JAK2) V617F mutation in 2005. This mutation was detected in 
90% of patients with polycythemia vera and 50% of patients with essential thrombo-
cytopenia and primary myelofibrosis. JAK2 is a member of the Janus family of tyrosine 
kinases. A retrospective analysis by Kiladjian showed that the detection of the JAK2 
V617F mutation was the first diagnostic step in the diagnosis of BCS basic research [59].
In China, Wang collected 65 cases of BCS blood samples from October 2009 to 
July 2010. EDTA-K2 anticoagulation treatment, DNA extraction, primer design, the 
establishment of allele-specific polymerase chain reaction system, and comparison 
of point mutations at nine sites between the study group and control group were 
performed. After allele-specific PCR, there were nine positive mutations in the study 
group JAK2 V617F with a mutation rate of 13.85% (9/65). The control group did not 
have this point mutation. The mutation rate of JAK2 V617F was significantly lower 
than that of BCS patients in Western countries. The results show that differences exist 
in the pathogenesis of Chinese BCS compared with that of Western countries [60].
6.1.4 Acquired condition
Many acquired conditions can provoke the occurrence of BCS. Acquired pre-
thrombotic lesions such as Behcet’s disease, antiphospholipid syndrome, hyperho-
mocysteinemia, and paroxysmal nocturnal hemoglobinuria (PNH) promote BCS 
development. Behcet’s disease, paroxysmal nocturnal hemoglobinuria, and oral 
contraceptives accounted for less than 1% of the study population.
6.2 Clinical manifestation and diagnosis
The clinical manifestations of portal hypertension caused by venous obstruction 
and posthepatitic cirrhosis and drug-induced (Gynura segetum) hepatitis are very 
similar, which often lead to misdiagnosis. For patients developing abdominal disten-
sion, hepatosplenomegaly, massive and refractory ascites, gastrointestinal bleeding, 
and hypersplenism leading to symptoms of white blood cells and thrombocytopenia, 
but without past medical history of hepatitis, chronic alcoholism, nor a history of 
taking Gynura segetum, hepatic venous occlusion should be considered. The clinical 
manifestations of inferior vena cava occlusion have characteristic signs including 
swelling, hyperpigmentation, varicose veins, and long-term unhealed ulcers of bilat-
eral lower extremities. In addition, bulging varicose veins above the skins of the chest 
and abdomen wall, longitudinal varicose veins, and the lower back varicose veins are 
also indicative of inferior vena cava occlusion (Figure 13a–f). Non-specific clinical 
Group Number Average VEGF 
concentration (ng/ml)
Standard 
error
t-value p-value
Control 
group
40 23.15 19.27 5.273 p < 0.001
Study group 40 5.63 8.38
Table 4. 
VEGF concentration value t-test result.
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manifestations of inferior vena cava obstruction include fatigue, exercise-induced 
asthma, irregular menstruation in women, habitual abortion, and primary infertility.
6.3 Imaging diagnosis
The diagnosis of BCS is based on the manifestations of hepatic venous outflow 
obstruction. This obstruction can be accurately displayed by noninvasive imaging such 
as Doppler ultrasound, CT, or magnetic resonance imaging (MRI). Doppler ultrasound 
is considered to be the preferred initial technique, with the ability to directly show 
the obstruction and reverse blood flow of the hepatic vein and inferior vena cava. The 
formation of collateral branches between hepatic veins is an indirect sign of hepatic vein 
obstruction. Ultrasound has a high sensitivity and specificity for the diagnosis of BCS.
CT scan and MRI are effective methods for diagnosing obstruction of the hepatic 
vein outflow tract. MR angiography is superior to CT, ultrasound, and angiography 
in demonstrating anatomic structures of the hepatic veins, accessory hepatic veins 
(AHV), inferior vena cava, azygous veins, and superficial veins of the abdominal 
wall (Figure 14a). Magnetic resonance angiography can directly display the hepatic 
veins, the inferior vena cava septum and its thickness, length of segmental occlusion 
of the inferior vena cava and hepatic vein, location and size of thrombus, as well as 
the location, orientation, thickness, and number of collateral circulations. Although 
it is not as effective as Doppler ultrasound in recording the intrahepatic collateral 
branches, it is unique in showing the extrahepatic collateral and collateral circula-
tions in the abdominal cavity and the abdominal wall (Figure 14b). MRI and CT 
Figure 13. 
Clinical manifestations. (a) Swelling of the lower extremities. (b) Varicose veins of the lower extremities.  
(c) Pigmentation of the lower extremities. (d) Ulcers of bilateral lower extremities. (e) Thoracic and 
abdominal wall varices. (f) Lumbar dorsal varices.
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can effectively show areas of liver parenchyma with reduced perfusion or necrosis. 
Magnetic resonance angiography not only makes the diagnosis of BCS more reli-
able but also facilitates the planning of treatment strategies. BCS can be precisely 
diagnosed by magnetic resonance angiography alone [61]; traditional percutaneous 
biopsy diagnosis of BCS may no longer be necessary [50].
Angiography is still the golden standard for the diagnosis of BCS. It comple-
ments ultrasound, CT, and MRI to provide comprehensive imaging diagnosis of 
BCS. At present, angiography is no longer used exclusively for diagnosis but also as 
a means of evaluating the efficacy of interventional therapy.
6.4 Definition of a membrane and segmental obstruction
Inferior vena cava and hepatic venous septum formation is a unique pathologi-
cal feature of BCS. Segmental obstruction can coexist in the inferior vena cava and 
hepatic vein in some circumstances, making pathological differentiation of the 
septum and segmentation difficult sometimes. Thus, proper differentiation of the 
septum and segmentation not only contribute to unified diagnostic criteria and 
straightforward description of multiple imaging inspection techniques but also 
promote subtyping BCS. Furthermore, it has significant clinical value for interven-
tional therapy. Therefore, it is necessary to define the inferior vena cava and hepatic 
venous septum and segmental obstruction.
In January 2016, we organized interventional radiology, pathology, and imaging 
diagnostic experts to analyze and discuss ultrasound, CT, MRI, and DSA images of 
more than 1000 patients with BCS and proposed the following viewpoints: inferior 
vena cava and hepatic vein “septum” and “segmentation” are defined by its thick-
ness, 5 mm or less as a membrane, 10 mm or more as a segment, and 6–9 mm as a 
transitional zone where the two differentiations can coexist [62].
6.5 Classification and subtype
Because the method of interventional therapy is utterly different from surgi-
cal treatment, the classification used for surgery is not suitable for interventional 
therapy. Imaging diagnosis of hepatic vein and inferior vena cava obstruction 
has become a routine. After summarizing and reviewing the clinical experi-
ence of 10,000 cases of interventional therapy in China, the conditions for the 
Figure 14. 
MRV images. (a) MRV directly shows the hepatic vein, inferior vena cava, and portal vein. (b) MRV shows 
extensive extrahepatic collateral circulations after inferior vena cava obstruction.
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establishment of BCS interventional classification have matured. Interventional 
classification will promote and standardize the behavior and procedures of BCS 
imaging diagnosis and interventional therapy. It has an objective, realistic, and 
long-term clinical significance.
In 2010, more than 10 experts in the Chinese Interventional Radiology Group 
engaged in developing an expert consensus guideline on interventional therapy of 
BCS. BCS is classified into three main types, namely, hepatic vein obstruction type, 
inferior vena cava obstruction type, and mixed type [63, 64], which are still widely 
used today. Because of the vast differences in the extent, number, and thrombosis 
of hepatic veins and the inferior vena cava between individuals, it is necessary to 
subtype BCS.
In January 2016, experts from the Intracavitary Catheterization Committee of 
the Chinese Medical Association and experts of interventional radiology, vascular 
surgery, pathology, and imaging diagnostics discussed to further divide the 3 major 
types of BCS into 10 subtypes (Table 5, Figures 15–24). For the first time, the 
hepatic vein and inferior vena cava obstruction combined with thrombosis were 
included in the subtype, before which none of the previous classifications have 
done so.
6.6 Subtyping of BCS as a guideline for endovascular therapy
Endovascular therapies for BCS include percutaneous balloon dilatation, 
stent implantation, thrombolysis, transjugular intrahepatic portosystemic shunt 
(TIPS), and hepatic vein reconstruction [65]. Approximately 98% of BCS patients 
benefit from interventional therapy. The difficulty of BCS intervention varies 
individually, depending on the procedures performed. Interventional treatment of 
inferior vena cava septum with a small opening is fairly simple. After completion 
of inferior vena cava angiography, dilation with a balloon of suitable diameter and 
length can be done straightforward. However, interventions involving inferior 
vena cava segmental occlusion, thrombosis formation, occlusion end with the for-
mation of collateral branches, or diffuse hepatic vein occlusion can take the opera-
tors hours or even days to complete the procedure. The new subtyping system 
provides a clear guideline for the preparation of preoperative treatment plannings 
and selection of equipment including medications and tools for thrombolysis, as 
well as the proper selection of percutaneous puncture routes and endovascular 
treatment methods (Table 6).
Hepatic vein obstruction 
subtypes
Inferior vena cava 
obstructive subtypes
Mixed-type occlusions
Hepatic vein/hepatic venous 
membranous obstruction 
(Figure 15)
Inferior vena cava 
membranous perforation 
(Figure 19)
Hepatic vein and inferior vena cava 
occlusion (Figure 23)
Hepatic venous segmental 
obstruction (Figure 16)
Inferior vena cava 
membranous obstruction 
(Figure 20)
Hepatic vein and inferior vena 
cava occlusion with thrombosis 
(Figure 24)
Extensive hepatic vein occlusion 
(Figure 17)
Inferior vena cava segmental 
obstruction (Figure 21)
Hepatic vein occlusion 
combined with thrombosis 
(Figure 18)
Inferior vena cava obstruction 
with thrombosis (Figure 22)
Table 5. 
Ten subtypes of Budd-Chiari syndrome.
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6.7 New perspectives
6.7.1 Anatomical occlusion versus functional occlusion
According to our data analysis of more than 2400 cases, the incidence of 
obstruction of the left hepatic vein in patients with BCS is higher than 95%. Due to 
the small volume and smaller venous return of the left hepatic lobe, the outcome 
of occlusion of the left hepatic vein is minimal since collateral branches can form 
between the left hepatic vein, right hepatic vein, and left inferior diaphragmatic 
vein. Due to the presence of the collateral branches, even if the left hepatic vein and 
the middle hepatic vein are occluded, venous return can be entirely compensated by 
the venous return of the right hepatic vein or accessory hepatic vein. Therefore, we 
Figure 15. 
Hepatic vein/hepatic venous membranous obstruction. (a) An ultrasound showing the septum at the left 
hepatic vein opening (arrow). (b) MRV showing the venous septum in the IVC (arrow). (c) DSA showing 
membranous venous occlusion in the right hepatic vein (arrow). (d) DSA showing membranous obstruction of 
the accessory hepatic vein (arrow).
Figure 16. 
Hepatic venous segmental obstruction. (a) An ultrasound showing the segmental obstruction (black arrow) 
of the right hepatic vein. (b) DSA showing segmental occlusion of the middle hepatic vein along with 
membranous obstruction (white arrow) of parahepatic venous structures.
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Figure 19. 
Inferior vena cava membranous obstruction with a tiny perforation. (a) Color-flow mapping showing 
membranous obstruction (black arrow) of the inferior vena cava. (b) MRI showing membranous obstruction 
(black arrow) of the inferior vena cava. (c) DSA showing membranous obstruction of the inferior vena cava 
with a tiny perforation (black arrow).
Figure 17. 
Extensive hepatic vein occlusion. (a) An ultrasound showing the right hepatic venous occlusion of the liver with 
hyperechoic texture. The right hepatic vein is faintly depicted (black arrow), and the left hepatic vein is small 
in caliber. (b) MR showing hepatosplenomegaly. Hepatic veins are few and small in calibers. (c) Enhanced CT 
showing hepatomegaly and heterogeneous parenchymal enhancements. (d) DSA showing the disappearance of 
the main trunk of the hepatic vein and small reticular-shaped collateral vessels.
Figure 18. 
Hepatic vein occlusion combined with thrombosis. (a) MRI showing the right hepatic vein occlusion with 
thrombosis (white arrow). (b) DSA showing hepatic venous occlusion with thrombosis (black arrow).
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still subtype cases with obstruction of the left hepatic vein and middle hepatic vein 
as isolated inferior vena cava obstruction type.
6.7.2 Accessory hepatic veins
In addition to the three hepatic veins, there are scattered small hepatic veins, 
collectively called the accessory hepatic vein (AHV) or the short hepatic veins, that 
drain directly into the IVC. After conducting anatomic researches, Liu et al. find 
that there are two primary sources of AHV: one is from the caudate lobar vein and 
the other from the right posterior hepatic vein. However, since most of the AHV are 
too small and are not the central draining vein of the liver, they are often neglected 
[65]. However, in patients with BCS, when hepatic vein occlusion occurs, AHV is 
Figure 20. 
Inferior vena cava membranous obstruction. (a) An ultrasound showing the vena cava septum as an echoic 
texture (white arrow). (b) MRV showing hypointense inferior vena cava septum (white arrow) right above the 
hepatic vein opening. (c) DSA showing membranous occlusion (black arrow) of the inferior vena cava.
Figure 21. 
Inferior vena cava segmental obstruction. (a) An ultrasound showing segmental occlusion (white arrows) of 
the inferior vena cava. (b) MRV showing a long segmental occlusion (black arrows) of the inferior vena cava. 
(c) DSA showing a long segmental occlusion (black arrows) of the inferior vena cava. (d) DSA projected in a 
lateral view showing an ultra-long segmental occlusion (black arrows) of the inferior vena cava.
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Figure 22. 
Inferior vena cava obstruction with massive thrombosis. (a) Gadolinium-enhanced MRI demonstrating 
massive thrombi of various ages (black arrows and white arrow) in the IVC below the level of obstruction. (b) 
DSA showing membranous obstruction in the IVC along with bulky thrombi (asterisk).
Figure 23. 
Hepatic vein and inferior vena cava occlusion. (a) MRI showing right hepatic venous membranous obstruction 
(white arrowhead) with segmental occlusion (black and white arrows) of the inferior vena cava. (b) DSA 
showing membranous occlusions of the right hepatic vein (black arrow) and inferior vena cava (white arrow).
Figure 24. 
Hepatic vein and inferior vena cava occlusions with thrombosis. (a) DSA showing right hepatic vein occlusion 
(black arrow) and IVC segmental occlusion with massive thrombosis (white arrow). (b) MRI showing 
occlusions of the hepatic vein (black arrows) and IVC with massive thrombi of various ages (asterisk).
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the main channel for venous return. Gai performed an ultrasound investigation 
on 244 BCS patients and found 191 (78.3%) cases presented with AHV. Among the 
244 BCS patients, 209 had hepatic caudate lobar veins with an average diameter of 
(7.88 ± 2.78) mm, and 147 had a right inferior hepatic vein with an average diameter 
of (9.50 ± 3.11) mm [66]. During expansion of the AHV lumen, collateral branches 
between the hepatic vein and the accessory hepatic vein can fully compensate the 
hepatic venous return (see Figure 21c). In cases accompanied with IVC obstruction, 
the degree of IVC obstruction aggravates the expansion of AHV lumen. The acces-
sory hepatic vein can also get obstructed. When the diameter of the AHV reaches 
6 mm, it has sufficient compensatory capacity. Therefore, the interventional 
treatment of the obstructed accessory hepatic vein above 6 mm is equivalent to the 
treatment of the hepatic vein. In short, the accessory hepatic vein is of equal value 
to the hepatic vein in the diagnosis and treatment of BCS [67].
Figure 25. 
MRV showing that the middle hepatic venous opening (hatched arrow) is above the inferior vena cava 
obstruction.
Subtype Endovascular therapy
Hepatic vein with membranous obstruction Balloon dilatation
Hepatic vein segmental obstruction Balloon dilatation + stent
Hepatic vein extensive obstruction TIPS, hepatic vein reconstruction
Hepatic vein occlusion with thrombosis Thrombolysis and balloon dilatation
Inferior vena cava membranous axonal Balloon dilatation
Inferior vena cava membranous obstruction Balloon dilatation
Inferior vena cava segmental obstruction Balloon dilatation + stent
Inferior vena cava obstruction with thrombosis Thrombolysis + balloon dilation/stent
Inferior vena cava and hepatic vein obstruction Balloon dilation/stent
Inferior vena cava and hepatic vein obstruction with thrombosis Thrombolysis + balloon dilation/stent
Table 6. 
Selection of endovascular treatment methods based on the subtypes of BCS.
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6.7.3 Inferior vena cava septum and position of hepatic vein opening
The location of the inferior vena cava septum is generally above the hepatic vein 
opening, often causing hepatic venous blood flow obstruction. As the number of 
BCS cases increases, we find cases with the left hepatic vein and middle hepatic vein 
locating above the inferior vena cava septum. Dr. Zhang of the Chinese Department 
of Vascular Surgery also found a case (Figure 25) with the hepatic vein opening 
directly above the inferior vena cava septum while providing surgical resection of 
inferior vena cava septum. Although the numbers of this kind of cases are excep-
tionally few, the consideration on redefining BCS may be raised.
6.7.4 Azygos veins and its collateral branches
When hepatic vein becomes obstructed, the establishment of collateral branches 
between the intrahepatic veins is simple, but it is difficult for collateral branches 
to develop outside of the liver. This can result in portal hypertension with poor 
prognosis. In contrast, the establishment of the collateral branches after the inferior 
vena cava obstruction is relatively easy and extensive (see Figure 26). The azygous 
vein is the most crucial collateral branch when inferior vena cava obstruction 
occurs. The azygous vein can expand to a diameter of 2 cm (Figure 21) and com-
pensate for the venous return of the inferior vena cava, and the patient usually can 
survive longer. Therefore, the severity of clinical symptoms of BCS is closely related 
to the compensatory capacity of the collateral circulation.
6.7.5 Closed collateral branch
After significant obstruction of the inferior vena cava, the superficial and deep 
vein begins to form collateral and communicating branches. In some cases, one or 
more collateral branches can appear above the site of inferior vena cava obstruc-
tion, with the diameter of reaching 2–3 mm. It can appear as single or multiple 
saclike structures, which are difficult to detect on preoperative ultrasound, CT, 
and MRV. However, DSA can easily show the obstruction and collateral branches 
Figure 26. 
MRV showing inferior vena cava obstruction with substantial azygos vein (black arrows) compensation.
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which play a vital blood flow compensation. During endovascular treatment, 
the existence of this collateral branch poses a potential risk. Since the collateral 
branches cannot be wholly identified under fluoroscopy, they may be ruptured 
during balloon dilatation, resulting in fatal intra-abdominal or intrathoracic 
bleeding. Thus, it is essential to be aware of this situation to ensure the safety of 
endovascular therapy.
7. Conclusion
With the adjunct use of PMAT incorporated in percutaneous CDT technology 
dedicated to the sophisticated endovascular management of DVT and DVT-related 
syndrome, the prevalence of PTS of moderate to severe degree and the intractable 
pain associated with advanced venous hypertension can be improved substantially. 
However, a randomized controlled study, comparing the adjunct use of PMAT 
or not, is demanded to offer convincing evidence. In conjunction with PTA and 
stenting after successful PMAT, symptomatic MTS can be well managed in terms 
of high technical success rate and midterm patency rate with acceptable minor 
complications. Along with the appreciations of newly identified pathophysiology 
and the creation of a new classification of subtypes, the selection of optimal mode 
of endovascular interventions in BCS may be solidly anticipated.
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